1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Sandoz Group AG

Sandoz Group AG

SDZNY
Sandoz Group AGUS flagOther OTC
95.15
USD
+1.59
- -
41.17BMarket Cap
Sandoz Group AG
SDZNY
(Other OTC)

Recent

price

95.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
FRC
21.59
23.21
24.14
25.83
Revenue per Share
1.97
0.18
- -
2.12
Basic EPS, GAAP
1.85
-0.61
0.14
1.88
Free Cash Flow per Basic Share
- -
- -
0.5
0.73
Dividend per Share
20.3
20.11
18.95
21.69
Book Value per Share
-0.33
-1.18
-1.81
-1.15
Tangible Book Value per Share
431
430
430
432
Basic Weighted Avg Shares
9,306
9,979
10,384
11,157
Sales/Revenue/Turnover
13.31
3.76
2.96
12.77
Operating Margin (%)
492
525
502
545
Depreciation Expense
848
77
- -
914
Net Income, GAAP
22.87
38.46
- -
24.28
Effective Tax Rate (%)
9.11
0.77
- -
8.19
Profit Margin (%)
-1,938
1,874
1,494
1,270
Working Capital
118
4,230
4,666
5,010
LT Debt
8,760
8,654
8,164
9,385
Total Equity
- -
1.98
- -
7.32
Return on Invested Capital (%)
- -
1.78
- -
7.7
Return on Capital (%)
- -
0.89
- -
10.42
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
14.96%
Free Cash Flow
- -
- -
1,250%
Net Income, GAAP
- -
- -
1,087.01%
Sales/Revenue/Turnover
- -
- -
7.44%
Total Cash Common Dividend
- -
- -
46.51%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
10,384
2025
- -
- -
- -
- -
11,157
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
2.12
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
0.73
2026
- -
- -
- -
- -
- -
Similar Companies
New You, Inc. (NWYU)
Orchid Pharma Limited (ORCHPHARMA.NS)
Sunniva Inc. (SNNVF)
Rubicon Organics Inc. (ROMJ.V)
Sandoz Group AG (SDZ.SW)
Vinergy Capital Inc. (VIN.CN)
Business
Sandoz Group AG operates as a prominent global entity in the realm of generic medications and biosimilars. The company is dedicated to the creation, production, and worldwide distribution of accessible, high-quality pharmaceutical products. Its portfolio encompasses a wide array of generic small-molecule medicines and complex biosimilar alternatives across various therapeutic categories, including cardiovascular, oncology, and central nervous system disorders. Sandoz also delivers active pharmaceutical ingredients and finished dose forms, particularly emphasizing its extensive range of anti-infectives, such as antibiotics. The organization spun off to become an independent public company in October 2023. Established in 1886, Sandoz maintains its headquarters in Basel, Switzerland.

Company News

Company News APIChatGPT

  • zacks.com

    NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?

  • zacks.com

    GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

  • prnewswire.com

    mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide

  • wsj.com

    Sandoz Gets Canada Approval for Generic Version of Ozempic

  • seekingalpha.com

    Sandoz Group AG (SDZNY) Analyst/Investor Day Transcript

  • zacks.com

    GRFS or SDZNY: Which Is the Better Value Stock Right Now?

  • reuters.com

    Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth

  • zacks.com

    3 Generic Drug Stocks to Watch Amid Improving Industry Trends

  • prnewswire.com

    Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

  • reuters.com

    Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

  • seekingalpha.com

    Sandoz Group AG (SDZNY) Q2 2026 Earnings Call Transcript

  • wsj.com

    Sandoz Shares Climb After Biosimilar Sales Drive Growth

  • reuters.com

    Sandoz results narrowly beat sales expectations

  • zacks.com

    UTHR or SDZNY: Which Is the Better Value Stock Right Now?

  • wsj.com

    Sandoz to Pay Around $480 Million to Settle U.S. Antitrust Pricing Litigations

  • reuters.com

    Sandoz agrees $450 mln settlement with 43 US states over antitrust claims

  • reuters.com

    Generic drug sector seeks policy fixes after Trump tariff threat

  • reuters.com

    Generic drugmaker Sandoz to engage with US after Trump tariff threat

  • reuters.com

    FDA set to review Sandoz's generic GLP-1s

  • zacks.com

    3 Generic Drug Stocks to Watch as New Growth Drivers Emerge